Intimation of receipt of marketing approval for trastuzumab biosimilar Dazublys from European Commission by Curateq Biologics s.r.o a wholly owned step down subsidiary of the Company.
Awaiting price reaction for this filing.
Curateq Biologics s.r.o, a wholly owned step-down subsidiary of the company, has received marketing approval from the European Commission for its trastuzumab biosimilar product called Dazublys. Trastuzumab is a widely used biologic for treating breast and stomach cancers, and this approval allows the product to be marketed across the European Union. Biosimilars are lower-cost alternatives to expensive biologic drugs, offering cost savings to healthcare systems. This is a significant regulatory milestone that opens up a major pharmaceutical market in Europe for the company.
This approval is a positive development as it unlocks access to the large European biosimilar market, potentially driving future revenue growth. However, the immediate stock price impact may be limited until commercial sales and revenue contribution are demonstrated.